share_log

TD Cowen Maintains Outperform on Takeda Pharmaceutical, Lowers Price Target to $20

Benzinga ·  May 16, 2023 19:19

TD Cowen analyst Ken Cacciatore maintains Takeda Pharmaceutical (NYSE:TAK) with a Outperform and lowers the price target from $30 to $20.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment